MedTrace Logo

Effectiveness and Safety of Firmagon®

NCT00930319 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 676

Last updated 2023-11-09

No results posted yet for this study

Summary

Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma. The period until Prostate Specific Antigen (PSA) progression during the Firmagon® therapy is to be documented and related to the testosterone values measured in the course of therapy (if available). Other clinical parameters, the patients' quality of life and the direct and indirect costs incurred by the medical care for the advanced hormone-dependent prostate carcinoma and its consequences will be evaluated. In this context the medical outcome and the life quality are defined as effectiveness and benefit value parameters. Both the effectiveness under daily life circumstances and economic variables of the therapy can thus be shown and compared within an analysis of costs vs. benefits or costs vs. effectiveness.

Conditions

  • Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma

Interventions

OTHER

Firmagon given by prescription according to SPC

Non-interventional,observational Firmagon given by prescription according to SPC

Sponsors & Collaborators

  • Ferring Arzneimittel GmbH

    collaborator INDUSTRY

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Clinical Development Support · Ferring Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00930319 on ClinicalTrials.gov